A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Inclusion criteria:

• Men and women with at least 1 eye with geographic atrophy (GA) secondary toage-related macular degeneration (AMD) determined by fundus autofluorescence (FAF).The total size of all GA lesions in the study eye (as determined by the independentcentral reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:

• If multiple lesions are present in the study eye, at least 1 lesion must havean area of ≥1.25 mm^2

• At least 1 GA lesion must be at least in part within a 1500 μm radius ringcentered on the fovea

• The foveal center point must not be involved in any atrophic lesion

• Lesion(s) must reside completely within the FAF 30 or 35 degree image

• Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using theearly treatment diabetic retinopathy study (ETDRS) chart (approximately equivalentto ≥20/100 on the Snellen chart).

• Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in thejunctional zone of GA in the study eye.

• Age ≥55 years.

• Men must be willing and able to use contraception (condom, abstinence) to preventpregnancy and/or exposure of an existing embryo or fetus to the investigationalproduct. A female participant is eligible if she is not a woman of childbearingpotential.

• Signed informed consent consistent with International Conference ofHarmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation

Exclusion criteria:

• Any history of, or evidence of, exudative age-related macular degeneration (eAMD) inthe study eye.

• Patients who received IVT treatment for GA (pegcetacoplan or avacincaptad pegol) for ≥12 months and/or received ≥6 injections in the study eye. Patients treated for <12months who have received <6 intravitreal (IVT) injections in the study eye may beincluded after a washout period of at least 4 months between the last injection andrandomization.

• Prior or ongoing investigational oral treatment for GA. A washout period of 4months, or 6 to 7 half-lives, whichever is longer, is acceptable.

• Additional eye disease in the study eye that could compromise BCVA or significantlyimpact retinal morphology:

• uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocularhypertension with intraocular pressure (IOP) >24 mmHg, or use of >2IOP-lowering medications in the study eye

• clinically significant diabetic retinopathy or maculopathy

• history of high myopia, i.e. spherical equivalent of ≥8 diopters or axiallength ≥27.2 mm

• anterior segment and vitreous abnormalities that would preclude adequateobservation with Spectral domain - optical coherence tomography (SD-OCT)

• other ocular conditions at the discretion of the investigator that mightinterfere with the outcome of the trial

• Significant disease or other medical conditions (as determined by medical history,examination, and clinical investigations at screening) that may, in the opinion ofthe investigator result in any of the following:

• put the participant at risk because of participation in the study

• influence the results of the study

• cause concern regarding the participant's ability to comply with the protocolrequirements or complete the trial as scheduled (e.g. chronic alcohol or drugabuse or any other condition that, in the investigator's opinion, makes theparticipant an unreliable trial participant)

• Known hypersensitivity to any of the ingredients used in the investigationalmedicinal product (IMP) formulation, or any of the medications used.

• Active intraocular inflammation in the study eye.

• Active infectious conjunctivitis in either eye. Further exclusion criteria apply.